Published in Obesity and Diabetes Week, January 12th, 2004
Under the terms of the agreement, Novo Nordisk will pay Genaissance license and service fees, including fees for genotyping clinical samples. Genaissance will have certain rights to develop and commercialize specified diagnostic products and services.
"We are pleased that Novo Nordisk chose our HAP Technology to address their pharmacogenomic need," said Kevin Rakin, president and CEO of Genaissance Pharmaceuticals.
"Novo Nordisk has been utilizing our good laboratory...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.